Abstract 1597P
Background
Cancer is the leading cause of death in Ireland, accounting for 28.5% of all deaths in 2021. Our aging population is predicted to drive a significant increase in new cancer cases in the coming decades. As such, high quality end-of-life care (EOLC) for patients dying in the acute hospital setting is an essential part of delivering holistic care to patients with cancer and their families. This is the second audit cycle to examine the quality of EOLC in one of the largest university teaching hospitals in Ireland. The first audit cycle, during the COVID-19 pandemic, identified several shortcomings in EOLC ( ESMO 2022 : S1134).
Methods
A care of dying patients guidance document, EOLC quality checklist, and staff education huddles facilitated by the Hospital Palliative Care Team were introduced in July 2022. A second retrospective chart review of patients who died under the care of the medical oncology service between 11th July 2022 and 30th April 2023 was performed. Data on the quality of EOLC delivered was collected and assessed using the published Oxford Quality Indicators for mortality review. An overall score for EOLC between 1 (very poor) and 5 (excellent) was assigned to each patient. These were compared with the previously presented 2021 cohort.
Results
We identified 72 patients (41 female). The median age at death was 65 years [23-89]. The mean length of admission resulting in death was 15.2 days [0-118]. The mean quality score for EOLC was 4.0, compared to 3.5 pre-intervention. Exploration of patient wishes, and spiritual care were documented in 45.8% and 58.3% of cases respectively, compared to 24.2% and 10.6% in the initial audit. 42 patients (58.3%) had care of the dying patient documents completed. The mean quality score for EOLC for these patients was 4.6, versus 3.2 for those without the document.
Conclusions
The quality of EOLC in our organisation has improved numerically in the second audit cycle. Areas of ongoing non-compliance to the Oxford Quality Indicators include exploration of patient wishes and spiritual care. The end-of-life committee, which now includes doctors in training, is committed to continuing to address deficits in the quality of EOLC in our institution, as an ESMO Designated Centre of Integrated Oncology and Palliative Care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05